Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Breast Cancer

Articles and resources on breast cancer for patients, caregivers, and family members

Helping People with Breast Cancer and Honoring Her Mom’s Legacy
By creating Debbie’s Friends Fund, Cherise Poserina found a way to remember her mother and support women fighting breast cancer. Read More ›

When Might You Want to Engage with Palliative Care?
For patients with metastatic breast cancer, “Involving palliative care as an active member of your oncology team early on is one of the smartest things you can do,” says national expert and breast cancer survivor Lillie Shockney. Read More ›

Share Your Upcoming Milestone Events with Your Treatment Team
For those dealing with metastatic breast cancer, national expert and breast cancer survivor Lillie Shockney stresses the importance of celebrating milestone events and joyful moments during treatment. Read More ›

Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›

From Silent Voices to “Hear My Voice”: People Living with Metastatic Breast Cancer Are Speaking Out
A national advocacy program trains patients with metastatic breast cancer to educate the public about the special needs of patients with advanced breast cancer. Read More ›

What Are Biomarkers in Breast Cancer, and How Do They Affect My Treatment? Interview with Daniel F. Hayes, MD, FACP, FASCO
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer. Read More ›

Finding Our Voices, Telling Our Stories: Metastatic Breast Cancer Advocacy
Musa Mayer, breast cancer survivor and advocate, was recently recognized for her 25 years of advocacy on behalf of patients with advanced breast cancer. Read Musa’s inspiring story. Read More ›

Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Press Releases — April 10, 2018
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer. Read More ›

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
Web Exclusives — April 7, 2018
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression. Read More ›

Blood-Based Biopsy Can Predict Breast Cancer Recurrence
Web Exclusives — February 26, 2018
In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease. Read More ›

Page 15 of 19